(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 April 2016 (28.04.2016)

WIPO | PCT

(10) International Publication Number
WO 2016/064969 A1

(51) International Patent Classification:
A61K 38/22 (2006.01) *A61K 38/10* (2006.01)
A61K 38/00 (2006.01)

(21) International Application Number:
PCT/US2015/056609

(22) International Filing Date:
21 October 2015 (21.10.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/066,862 21 October 2014 (21.10.2014) US
62/215,433 8 September 2015 (08.09.2015) US

(71) Applicant: **SCICLONE PHARMACEUTICALS, INC.** [US/US]; 950 Tower Lane, Suite 900, Foster City, California 94404 (US).

(72) Inventors: **KING, Robert S.**; 365 Castro Lane, Fremont, California 94539 (US). **TUTHILL, Cynthia**; 33096 N Front Street, Hercules, California 94547 (US). **BLOBEL, Friedhelm**; c/o Sciclone Pharmaceuticals, Inc., 950 Tower Lane, Suite 900, Foster City, California 94404 (US).

(74) Agents: **WU, Nan** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW Suite 700, Washington, District of Columbia 20004-2400 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:


— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: TREATMENT OF CANCER WITH IMMUNE STIMULATORS

FIG. 6A



(57) Abstract: The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and/or optionally one or more additional anti-cancer agents.

WO 2016/064969 A1